EMAIL SIGN UP!
Most Popular This Week
- Scared to Death in the USA
- We’re Not Broke — We’ve Been Robbed
- With Scant Media Attention, 'Human Catastrophe of Epic Proportions' Unfolding
- Wave of Black Friday Strikes Kicks Off as Walmart CEO Steps Down
- The Empire Strikes Back: How Wall Street Has Turned Housing Into a Dangerous Get-Rich-Quick Scheme -- Again
Today's Top News
Charting a New Course at the FDA
On March 14, President Obama nominated Margaret Hamburg to become commissioner of the FDA and appointed Joshua Sharfstein, a longtime critic of the pharmaceutical industry, as her principal deputy. Sharfstein, who does not need Senate approval, took over the agency as acting commissioner last week, pending Hamburg's confirmation. His appointment gives real hope that the FDA will stop kowtowing to the big drug companies. For too long the agency has behaved as though its job is to speed brand-name drugs to market, not to ensure that they are safe and effective. But while new leadership is crucial, more needs to be done.
First, Congress should repeal the Prescription Drug User Fee Act. This 1992 law, renewable every five years, authorizes drug companies to pay "user fees" to the FDA for every drug the agency considers for approval. That puts the FDA on the payroll of the industry it regulates, and makes it more likely that drugs will be reviewed favorably - a bargain for drug companies. Drug companies should not be considered "users" of the FDA; the public is the user, and it alone should support the agency.
Second, consultants for drug companies should no longer be permitted to serve on FDA advisory panels. These panels consist of outside experts who advise the FDA on whether drugs should be approved, and their recommendations are nearly always followed. But many panel members double as paid consultants for drug companies. Although they are supposed to recuse themselves from decisions in which they have a large, direct financial interest, that requirement is often waived. There is no reason to tolerate any conflicts of interest in such key positions.
Third, the agency should see that the post-marketing studies it mandates are actually carried out. Some drugs are approved on condition that further studies are done after they are on the market, mainly to make sure there are no serious side-effects that did not show up in the pre-marketing clinical trials. Drug companies agree to these studies, but then renege on their commitments. More than 1,000 such studies haven't been started, thus exposing the public indefinitely to drugs of uncertain safety.
Fourth, the FDA should review generic drugs as fast as brand-name drugs. A key to lowering drug prices is to get generic drugs to market quickly after their brand-name counterparts lose their exclusive marketing rights. Drug companies want to delay the appearance of generic drugs as long as possible, and the FDA helps by taking roughly twice as long to approve them as to approve brand-name drugs.
Fifth, Congress should give the FDA the authority to require drug companies to compare new drugs with existing drugs of the same type. Most newly approved drugs are trivial variations of top-selling drugs on the market. Called "me-too" drugs, they are especially profitable, because they usually target ill-defined medical conditions - huge markets that are easily expanded. For example, there are now five drugs of the SSRI type (that is, with the same mechanism of action) to treat depression. Me-too drugs are approved if clinical trials show they are better than placebos, but they don't have to be compared with another drug of the same type. We simply don't know whether a new me-too drug is better or worse than the others, although they are always marketed as though they have some advantage.
Sixth, the FDA should stop approving me-too drugs on the basis of surrogate endpoints. A surrogate endpoint is a measurement that is thought to be related to a clinical outcome. For example, cholesterol level is a surrogate endpoint for heart attacks or strokes. But surrogate endpoints do not always have the expected predictive value. It makes sense to rely on them in clinical trials of drugs to treat serious conditions for which there are no existing treatments of the same type, because such trials are faster, even if sometimes misleading. But for me-too drugs, there is no rush and the FDA should insist on clinical endpoints.
Finally, the FDA should prohibit direct-to-consumer advertising for three years after drugs are approved. Every newly approved drug has been tested only under controlled conditions in relatively small numbers of patients. Once drugs come into widespread use, unanticipated risks may become apparent. In recent years, a record number of drugs have had to be withdrawn from the market because they turned out to be dangerous. If new drugs are heavily advertised, people may be unnecessarily exposed to risks.
It is time to restore the FDA to its purpose, which is to protect the public from unsafe food, drugs, and devices, not to accommodate the industries it regulates. The change in leadership is reason for optimism.